Michael Rezaian, MD
Rheumatology · Martinsburg, WVNPI 1598821449
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Novartis accounts for 75.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2024 at $3,726 and has fallen 94.6% since, to $203 in 2025.
Across 105 payments — averaging $51.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Johnson & Johnson$463
- Pfizer$240
- GSK$230
- AbbVie$188
- E.r. Squibb & Sons, L.L.C.$72
- plus $169 from 5 others
What the payments were for
- Consulting fees$3,25060%
- Travel & lodging$2975%
- Food & beverage$1,75032%
- Education$1523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 25 | $4,087 |
| Johnson & Johnson | 31 | $463 |
| Pfizer | 21 | $240 |
| GSK | 12 | $230 |
| AbbVie | 5 | $188 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Eli Lilly | 1 | $61 |
| Amgen(2 entities) | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Sanofi | 1 | $16 |
| Radius Health, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,449 in reported general payments places this provider in the 70th percentile of 26 rheumatology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 411 | $2,022,300 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 232 | $1,942,725 |
| RinvoqUpadacitinib | 276 | $1,875,066 |
| Cosentyx Sensoready PenSecukinumab | 222 | $1,746,451 |
| Enbrel SureclickEtanercept | 184 | $1,404,512 |
| Skyrizi PenRisankizumab-Rzaa | 42 | $865,196 |
| Humira(Cf) PenAdalimumab | 90 | $824,164 |
| Xeljanz XrTofacitinib Citrate | 93 | $529,301 |
| TremfyaGuselkumab | 34 | $457,016 |
| Taltz AutoinjectorIxekizumab | 65 | $450,974 |
| Cimzia (2 Pack)Certolizumab Pegol | 55 | $326,459 |
| Humira PenAdalimumab | 34 | $281,508 |
| Humira(Cf)Adalimumab | 14 | $188,414 |
| Orencia ClickjectAbatacept | 25 | $143,461 |
| XeljanzTofacitinib Citrate | 24 | $135,941 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $188 | $2,063,481290 claims |
| AmgenOtezla, Prolia | $40 | $2,053,702429 claims |
| Johnson & JohnsonTremfya, Remicade, Simponi | $463 | $631,70060 claims |
| PfizerXeljanz | $240 | $135,94124 claims |
| GSKBenlysta | $230 | $101,89221 claims |
| SanofiKevzara | $16 | $59,11214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 26 rheumatology providers in West Virginia.
Other rheumatology in Martinsburg
- Arash HassantoufighiMartinsburg$5K
- Wassim SaikaliBeckley$1.1M
- Suzanne GharibSouth Charleston$581K
- Michael IstfanSouth Charleston$25K
- Mirza BegHuntington$20K
- Leah TriplettCharleston$19K
- Brian HoustonMorgantown$10K
- Charles JusticeCharleston$6K
- Silera Holguin BalbuenaCharleston$3K
- Munib AftabMorgantown$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.